Skip to main content

Table 1 Baseline characteristics of participants according to dyskinesia and OAB

From: Unraveling the interplay between dyskinesia and overactive bladder symptoms in Parkinson’s disease: a comprehensive cohort study based on the long-term follow-up database of Parkinson’s disease

Characteristics

Total

Dyskinesia

Urgency

Nocturia

Frequency

N

Ysig(N vs. Y)

N

Ysig(N vs. Y)

N

Ysig(N vs. Y)

N

Ysig(N vs. Y)

Gender (male%)

788(58.89%)

617(46.11%)

171(12.78%)ns

561(41.93%)

227(16.97%)ns

482(36.02%)

306(22.87%)ns

598(44.69%)

190(14.20%)ns

Age

64(57,70)

63(56,70)

65(60,70) *

63(56,70)

65(58,71)ns

62(55,69)

65(59,71)***

63(56,70)

66(60,71) ***

Duration

36(22,69)

36(17,60)

67(36,108)***

36(18,60)

48(24,84)***

36(17,60)

48(24,84)***

36(18,60)

56(24,96)***

Onset

60(53,66)

60(53,67)

59(51,65)*

60(53,66)

60(52,66)ns

59(52,66)

60(54,66.25)ns

59(53,66)

61(53.5,66)ns

LEDD

337.5(200,525)

300(200,450)

525(306,775)***

300(200,475)

400(300,650)***

300(187.5,450)

400(300,600)***

300(200,450)

450(300,675)***

UPDRS I

3(1,4)

2(1,4)

3(2,5)***

2(1,4)

3(2,5)***

2(1,4)

3(2,5)***

2(1,4)

3(2,5)***

UPDRS II

10(7,14)

9(6,12)

14(10,18.75)***

9(6,13)

11(8,16)***

9(6,12)

11(8,16)***

9(6,13)

12(8,18)***

UPDRS III

23(15,33)

21(13,29.25)

32(23,39.75)***

21(14,30)

28(19,37)***

21(13,29)

28(19,36)***

21(14,30)

29(19.5,37.5)***

UPDRS IV

1(0,3)

0(0,2)

5(4,6)***

1(0,2)

3(1,5)***

1(0,2)

2(0,5)***

1(0,2)

4(1,5)***

H-Y

2(1.5,2.5)

2(1.5,2.5)

2.5(2,3)***

2(1.5,2.5)

2.5(2,3)***

2(1.5,2.5)

2.5(2,3)***

2(1.5,2.5)

2.5(2,3)***

Frequency

331(24.74%)

154(11.51%)

177(13.23%)***

130(9.72%)

201(15.02%)***

110(8.22%)

221(16.52%)***

-

-

Urgency

408(30.49%)

222(16.59%)

186(13.90%)***

-

-

124(9.27%)

284(21.23%)***

207(15.47%)

201(15.02%)***

Nocturia

540(40.36%)

337(25.19%)

203(15.17%)***

256(19.13%)

284(21.23%)***

-

-

319(23.84%)

221(16.52%)***

Dyskinesia

298(22.27%)

-

-

112(8.37%)

186(13.90%)***

95(7.10%)

203(15.17%)***

121(9.04%)

177(13.23%)***

NMSQ

7(5,9)

7(4,8)

8(7,13) ***

7(4,7)

9(7,13)***

6(3,7)

8(7,13) ***

7(4,7)

10(7,14) ***

MMSE

27(24,29)

27(24,29)

26(22,28)***

27(24,29)

26(23,28)**

27(24.25,29)

26(23,28)***

27(24,29)

26(23,28)***

MoCA

23(20,25)

23(20,25)

23(20,25)ns

23(19,25)

23(20,25)ns

23(20,25)

23(20,26) ns

23(19,25)

23(21,25) ns

  1. Abbreviations: LEDD Levodopa equivalent daily dose, UPDRS I-III Unified Parkinson’s Disease Rating Scale I-III, H-Y: Hoehn-Yahr Scale, MMSE The Mini Mental State Examination, MoCA Montreal Cognitive Assessment, NMSQ None Motor Symptom Questionnaire, sig significance, ns: not significant, ***p < 0.001, **p < 0.01,*p < 0.05